| Atos Se ATOS ORD SHS | 51.79 / -0.56% |
| Date/Time | 06/23 / 19:09 |
| Chg. / Chg.(%) | -0.29 / -0.56% |
| Bid | - |
| Ask | - |
| Open | 52.62 |
| Previous Close | 52.08 |
| High | 52.90 |
| Low | 51.68 |
| Volume [EUR] | 16,174,605.59 |
| Volume [Units] | 456,168 |
| Price fixings | 222 |
| ISIN | FR0000051732 |
| Security | 0DNH |
| Exchange | London International |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Euronext - P.. | 51.68 |  |
604,198 |
| London Inter.. | 51.79 | |
456,168 |
| Cboe Europe .. | 51.74 | |
181,850 |
| Turquoise | 51.72 | |
63,502 |
| Cboe Europe .. | 51.91 | |
2,149 |
| TradeGate | 52.000 | |
1,403 |
| Quotrix | 51.9400 | |
300 |
| Frankfurt | 51.7000 | |
104 |
| gettex | 52.100 | |
24 |
| Vienna Globa.. | 51.78 | |
0 |
| Berlin | 51.90 |  |
0 |
| Düsseldorf | 52.02 | |
0 |
| München | 51.88 | |
0 |
| Stuttgart | 51.920 | |
0 |
| Lang & Schwa.. | 52.020 | |
|
| Nasdaq Other.. | 62.0000 | 1,000 | |
| Cboe Europe .. | 52.81 | 1,002 | |
| EUREX | Options | ||
News
- Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
06/16/2021 / 15:00 - GlobeNewswire - Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
06/11/2021 / 15:00 - GlobeNewswire - Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
06/09/2021 / 15:00 - GlobeNewswire - Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
06/07/2021 / 15:00 - GlobeNewswire - Mobiquity Technologies Adds Contextual Targeting to AdCreatr Providing a Seamless Integration into Privacy Compliant Ad Creative and Targeting
06/04/2021 / 14:00 - GlobeNewswire
Real-time